Watch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
Kincell Bio announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs). Under...
This webinar explores how integrated PD/AD expertise can deliver robust, regulatory-ready assays and accelerates cell therapy development.
Cell therapies hold curative potential, yet far too many patients still can’t access them. In many cases, these treatments aren’t pursued by developers because science...
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs are stalling, and...
DownloadKincell Bio announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs). Under...
Read MoreCell therapies hold curative potential, yet far too many patients still can’t access them. In many cases, these treatments aren’t pursued by developers because science...
Read MoreResearch Triangle Park, NC — Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the promotion of three accomplished executives...
Read MoreMark R. Bamforth OBE Transitions to Executive Chair of the Board, Strengthening Strategic Leadership at Kincell Bio Research Triangle Park, NC — Kincell Bio, a leading...
Read MoreAs allogeneic cell therapies advance toward commercialization, manufacturers must adopt automation and flexible facility designs to improve scalability, consistency, and cost efficiency.
1622 NW 55th Place
Gainesville, FL 32653
20 TW Alexander Dr, Suite 130
RTP, NC 27713
